PDF(544 KB)
单中心MAE方案诱导治疗儿童急性髓系白血病的合并症及疗效分析
陈晓燕, 阮敏, 赵贝贝, 王书春, 陈晓娟, 张丽, 郭晔, 杨文钰, 邹尧, 陈玉梅, 竺晓凡
中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (1) : 24-28.
PDF(544 KB)
PDF(544 KB)
单中心MAE方案诱导治疗儿童急性髓系白血病的合并症及疗效分析
Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes
目的 回顾性分析米托蒽醌、阿糖胞苷联合依托泊苷（MAE）方案诱导治疗初诊儿童急性髓系白血病（AML）的合并症发生情况及疗效。方法 170例AML患儿采用MAE方案诱导治疗，分析诱导治疗后的合并症及缓解率。结果 170例中男女比例为1.33：1，年龄7.4（1~15）岁，诊断时WBC 29.52（0.77~351）×109/L，其中M0 2例、M2 24例、M4 2例、M5 48例、M6 3例、M7 7例，AML伴有t（8；21）（q22；q22）69例，AML伴有inv（16）（p13.1q22）或t（16；16）（p13.1；q22）15例。最常见的合并症为感染，占92.9%，其中无明确感染灶的粒缺伴发热占13.9%（22/158），有明确感染病灶（包括血流感染）的占86.1%（136/158）；其他合并症包括非感染性腹泻、出血、药物性肝炎等。治疗相关死亡10例，其中严重感染8例、多脏器功能衰竭1例、呼吸衰竭1例。156例进行了缓解率评估，完全缓解率85.3%、部分缓解率4.5%、未缓解率10.3%。结论 MAE方案治疗儿童AML的1疗程诱导缓解率较好，合并症及治疗相关死亡原因以感染为主。
Objective To investigate the complications and clinical outcome of children with acute myeloid leukemia (AML) undergoing mitoxantrone-cytarabine-etoposide (MAE) induction therapy. Methods A total of 170 children with AML were given MAE induction therapy, and the complications and remission rate were analyzed after treatment. Results The male/female ratio was 1.33:1 and the mean age was 7.4 years (range 1-15 years). Leukocyte count at diagnosis was 29.52×109/L[range (0.77-351)×109/L]. Of all children, 2 had M0-AML, 24 had M2-AML, 2 had M4-AML, 48 had M5-AML, 3 had M6-AML, 7 had M7-AML, 69 had AML with t(8;21)(q22;q22), and 15 had AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22). The most common complication was infection (158/170, 92.9%). Among these 158 patients, 22 (13.9%) had agranulocytosis with pyrexia (with no definite focus of infection), and 136 (86.1%) had definite focus of infection (including bloodstream infection). Other complications included non-infectious diarrhea, bleeding, and drug-induced hepatitis. Treatment-related mortality was observed in 10 children, among whom 8 had severe infection, 1 had multiple organ failure, and 1 had respiratory failure. Remission rate was evaluated for 156 children and the results showed a complete remission rate of 85.3%, a partial remission rate of 4.5%, and a nonremission rate of 10.3%. Conclusions Induction therapy with the MAE regimen helps to achieve a good remission rate in children with AML after one course of treatment. Infection is the main complication and a major cause of treatmentrelated mortality.
Acute myeloid leukemia / Induction therapy / Complication / Child
[1] Papaemmanui E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia[J]. N Engl J Med, 2016, 374(23):2209-2221.
[2] Gamis AS, Alonzo TA, Perentesis JP, et al. Children's Oncology Group's 2013 blueprint for research:acute myeloid leukemia[J]. Pediatr Blood Cancer, 2013, 60(6):964-971.
[3] Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia:a retrospective analysis of the AML-BFM trials from 1987 to 2012[J]. Leukemia, 2018, 32(10):2167-2177.
[4] Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J]. Blood, 2009, 114(5):937-951.
[5] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版. 北京:科学出版社, 1999:131-134.
[6] U.S. Department of Health and Human Services, National Institutes of Health/National Cancer Institute. Terminology Criteria for Adverse Events (CTCAE) version 4.0.3[EB/OL]. (May 28, 2009). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
[7] Zwaan CM, Kolb EA, Reinhard D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia[J]. J Clin Oncol, 2015, 33(27):2949-2962.
[8] Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia:the AML99 trial from the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol, 2009, 27(24):4007-4013.
[9] Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia:analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98[J]. J Clin Oncol, 2004, 22(21):4384-4393.
[10] Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia:analysis of the prospective multi-institutional clinical trial AML-BFM 93[J]. Leukemia, 2004, 18(1):72-77.
[11] Inaba H, Gaur AH, Cao X, et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia[J]. Cancer, 2014, 120(13):1985-1992.
[12] Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML:a report from the Children's Oncology Group[J]. Blood, 2013, 121(18):3573-3577.
[13] Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia:results of AML-BFM 98[J]. J Clin Oncol, 2006, 24(27):4499-4506.
[14] Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colonystimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse[J]. J Clin Oncol, 2010, 28(15):2591-2597.
[15] Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer:a meta-analysis of randomized controlled trials[J]. J Clin Oncol, 2004, 22(16):3350-3356.
[16] Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4):424-447.
